biostudies-literatureConte BMinistero della SaluteEuropean Research CouncilMinistero della Salute (Italy Ministry of Health)5217-5226https://www.ebi.ac.uk/biostudies/studies/S-EPMC10722129biostudies-literatureUnknown29(24)<h4>Purpose</h4>In estrogen receptor-positive (ER+) breast cancer, single-nucleotide polymorphisms (SNP) in the aromatase gene might affect aromatase inhibitors (AI) metabolism and efficacy. Here, we assessed the impact of SNP on prognosis and toxicity of patients receiving adjuvant letrozole.<h4>Experimental design</h4>We enrolled 886 postmenopausal patients in the study. They were treated with letrozole for 2 to 5 years after taking tamoxifen for 2 to 6 years, continuing until they completed 5 to 10 years of therapy. Germline DNA was genotyped for SNP rs4646, rs10046, rs749292, and rs727479. Log-rank test and Cox model were used for disease-free survival (DFS) and overall survival (OS). Cumulative incidence (CI) of breast cancer metastasis was assessed through competing risk analysis, wiClinical cancer research : an official journal of the American Association for Cancer ResearchSNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.PMC10722129odowska&amp;#x2013Curie grant agreement No 955951Marie Sk&amp;#x0142Prat ACardinali BGenerali DMansutti MRossi MGori SSchettini FFrassoldati ANotaro RPiccioli PLambertini MDel Mastro LLastraioli STurletti AScognamiglio GConte BDurando AMontemurro FPoggio FTamberi SLunardi GDe Angioletti MBisagni GSerra MBraso-Maristany FPuglisi FGarrone OSanna GDe Placido SPorpiglia MBighin CBoni LFabi APonzone RPazzola AfalseSNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.<h4>Purpose</h4>In estrogen receptor-positive (ER+) breast cancer, single-nucleotide polymorphisms (SNP) in the aromatase gene might affect aromatase inhibitors (AI) metabolism and efficacy. Here, we assessed the impact of SNP on prognosis and toxicity of patients receiving adjuvant letrozole.<h4>Experimental design</h4>We enrolled 886 postmenopausal patients in the study. They were treated with letrozole for 2 to 5 years after taking tamoxifen for 2 to 6 years, continuing until they completed 5 to 10 years of therapy. Germline DNA was genotyped for SNP rs4646, rs10046, rs749292, and rs727479. Log-rank test and Cox model were used for disease-free survival (DFS) and overall survival (OS). Cumulative incidence (CI) of breast cancer metastasis was assessed through competing risk analysis, wi2023-01-01T00:00:00Z2023 Dec2026-05-29T08:09:39.188Z2024-11-20T22:56:39.313ZS-EPMC107221293788829910.1158/1078-0432.CCR-23-1568